Donor-derived cell free DNA as a biomarker in kidney transplantation

Tarek Abdulhadi; Louai Alrata; Casey Dubrawka; Gwendolyn Amurao; Sri Mahathi Kalipatnapu; Che Isaac; Shelden Rodrigues; Karen Marie Flores; Dema Yaseen Alsabbagh; Omar Alomar; Tarek Alhamad

doi:10.2217/pgs-2023-0138

Donor-derived cell free DNA as a biomarker in kidney transplantation

Tarek Abdulhadi, Louai Alrata, Casey Dubrawka, Gwendolyn Amurao, Sri Mahathi Kalipatnapu, Che Isaac, Shelden Rodrigues, Karen Marie Flores, Dema Yaseen Alsabbagh, Omar Alomar, Tarek Alhamad

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

The early detection of acute rejection in the allograft is important as it provides an opportunity for timely therapeutic intervention in order to preserve graft function and achieve longer graft survival. Donor-derived cell-free DNA (dd-cfDNA) has emerged as a new biomarker in the field of kidney transplantation. In this review, we used data from various studies to examine the role of dd-cfDNA in comparison to creatinine and donor-specific antibodies in the early detection of transplant rejection. We also reviewed the use of dd-cfDNA in other organ transplants as well as the challenges and potential future direction for dd-cfDNA as a diagnostic tool.

Original language	English
Pages (from-to)	771-780
Number of pages	10
Journal	Pharmacogenomics
Volume	24
Issue number	14
DOIs	https://doi.org/10.2217/pgs-2023-0138
State	Published - Sep 1 2023

Keywords

biomarker
cell-free DNA
cfDNA
ddcfDNA
donor derived cell-free DNA
kidney
rejection
transplant

Access to Document

10.2217/pgs-2023-0138

Cite this

@article{fad958b6f0f04c2a86c3d291d03d33c9,

title = "Donor-derived cell free DNA as a biomarker in kidney transplantation",

abstract = "The early detection of acute rejection in the allograft is important as it provides an opportunity for timely therapeutic intervention in order to preserve graft function and achieve longer graft survival. Donor-derived cell-free DNA (dd-cfDNA) has emerged as a new biomarker in the field of kidney transplantation. In this review, we used data from various studies to examine the role of dd-cfDNA in comparison to creatinine and donor-specific antibodies in the early detection of transplant rejection. We also reviewed the use of dd-cfDNA in other organ transplants as well as the challenges and potential future direction for dd-cfDNA as a diagnostic tool.",

keywords = "biomarker, cell-free DNA, cfDNA, ddcfDNA, donor derived cell-free DNA, kidney, rejection, transplant",

author = "Tarek Abdulhadi and Louai Alrata and Casey Dubrawka and Gwendolyn Amurao and Kalipatnapu, {Sri Mahathi} and Che Isaac and Shelden Rodrigues and Flores, {Karen Marie} and Alsabbagh, {Dema Yaseen} and Omar Alomar and Tarek Alhamad",

note = "Publisher Copyright: {\textcopyright} 2023 Future Medicine Ltd.",

year = "2023",

month = sep,

day = "1",

doi = "10.2217/pgs-2023-0138",

language = "English",

volume = "24",

pages = "771--780",

journal = "Pharmacogenomics",

issn = "1462-2416",

number = "14",

}

TY - JOUR

T1 - Donor-derived cell free DNA as a biomarker in kidney transplantation

AU - Abdulhadi, Tarek

AU - Alrata, Louai

AU - Dubrawka, Casey

AU - Amurao, Gwendolyn

AU - Kalipatnapu, Sri Mahathi

AU - Isaac, Che

AU - Rodrigues, Shelden

AU - Flores, Karen Marie

AU - Alsabbagh, Dema Yaseen

AU - Alomar, Omar

AU - Alhamad, Tarek

PY - 2023/9/1

Y1 - 2023/9/1

N2 - The early detection of acute rejection in the allograft is important as it provides an opportunity for timely therapeutic intervention in order to preserve graft function and achieve longer graft survival. Donor-derived cell-free DNA (dd-cfDNA) has emerged as a new biomarker in the field of kidney transplantation. In this review, we used data from various studies to examine the role of dd-cfDNA in comparison to creatinine and donor-specific antibodies in the early detection of transplant rejection. We also reviewed the use of dd-cfDNA in other organ transplants as well as the challenges and potential future direction for dd-cfDNA as a diagnostic tool.

AB - The early detection of acute rejection in the allograft is important as it provides an opportunity for timely therapeutic intervention in order to preserve graft function and achieve longer graft survival. Donor-derived cell-free DNA (dd-cfDNA) has emerged as a new biomarker in the field of kidney transplantation. In this review, we used data from various studies to examine the role of dd-cfDNA in comparison to creatinine and donor-specific antibodies in the early detection of transplant rejection. We also reviewed the use of dd-cfDNA in other organ transplants as well as the challenges and potential future direction for dd-cfDNA as a diagnostic tool.

KW - biomarker

KW - cell-free DNA

KW - cfDNA

KW - ddcfDNA

KW - donor derived cell-free DNA

KW - kidney

KW - rejection

KW - transplant

UR - http://www.scopus.com/inward/record.url?scp=85177025900&partnerID=8YFLogxK

U2 - 10.2217/pgs-2023-0138

DO - 10.2217/pgs-2023-0138

M3 - Review article

C2 - 37732393

AN - SCOPUS:85177025900

SN - 1462-2416

VL - 24

SP - 771

EP - 780

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 14

ER -

Donor-derived cell free DNA as a biomarker in kidney transplantation

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this